Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · Apr 2017
[A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP). The development of BTP may contribute to less-effective analgesia, a reduced satisfaction with analgesia therapy, obstacles in daily life, mood disorders, and an increased use of healthcare resources. In most BTP, both the duration from BTP onset to its maximum intensity and the overall duration of BTP episodes are relatively short. ⋯ OTFC may also be safely used for patients with renal dysfunction. Since the drug has many characteristics that differ from conventional rapid-release preparations, it is important to become familiar with the use of OTFC. In order to address improving the QOL of cancer patients, a comprehensive assessment of the patient, including the risk of BTP being inadequately controlled by conventional rescue preparations is necessary.
-
Gan To Kagaku Ryoho · Nov 2016
Case Reports[A Case of Small Intestinal Malignant Lymphoma Presenting with Perforated Peritonitis].
An 85-year-old man presented to the emergency department with vomiting. He had tenderness in the left abdomen and under the umbilicus. Laboratory data showed an increase in the inflammatory response. ⋯ Two cycles ofchemotherapy were given post-operatively. A recurrence was not observed. After chemotherapy he was transferred to rehabilitation.
-
Gan To Kagaku Ryoho · Nov 2016
Case Reports[Stage IV Gastric Cancer with Positive Peritoneal Washing Cytology or Peritoneal Dissemination Was Successfully Treated with Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy(HIPEC)Followed by Systemic Chemotherapy - A Report of Two Cases].
Survival of Stage IV gastric cancer is poor. We report 2 cases of Stage IV gastric cancer with positive peritoneal washing cytology or peritoneal dissemination that were successfully treated with gastrectomy and hyperthermic intraperitoneal chemotherapy( HIPEC)followed by systemic chemotherapy. Case 1: A 59-year-old woman. ⋯ After the surgery, she underwent chemotherapy, 35 courses of combination S-1 plus PSK/DOC, and 13 courses of S-1 plus PSK. It has been 5 years since her surgery and she survives without exacerbation of the cancer. These cases suggest a gastrectomy and HIPEC followed by systemic chemotherapy may represent an effective treatment for advanced gastric cancer with a small amount of peritoneal metastasis.
-
Gan To Kagaku Ryoho · Aug 2016
[Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
In Japan, cardiovascular diseases are frequent complications in cancer patients owing to the rapidly aging population and changes in the overall lifestyle. In addition, cancer itself including advanced cancer, and certain therapies used to treat it, often cause further cardiovascular complications. Moreover, although the recently developed molecularly targeted cancer drugs have improved patient prognosis, unexpected cardiovascular side effects, especially cardiotoxicity, have become an important limitation of cancer therapy. ⋯ As such, cardiologists should fully understand these molecularly targeted therapies and the potential pathogenic mechanisms at molecular levels. To protect cancer patients from cardiotoxicity, further basic and clinical research on the pathogenesis and mechanisms of cardiotoxicity of the molecularly targeted cancer drugs is of paramount importance. Furthermore, in-depth research in these areas could potentially result in new insights about onco-cardiology and cardiovascular medicine.
-
Gan To Kagaku Ryoho · May 2016
Case Reports[A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab].
Lymphangitis carcinomatosa of the lung is intractable and associated with a poor prognosis. ⋯ Chemotherapy including bevacizumab facilitated long-term survival (52 months) of a patient with lung adenocarcinoma accompanied by lymphangitis carcinomatosa and multiple bone metastases.